echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > 225 million US dollars introduced!

    225 million US dollars introduced!

    • Last Update: 2021-05-09
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    The Center for Drug Evaluation (CDE) of the State Food and Drug Administration of China has announced that the IMG-020 injection declared by Chuangxiang Biotechnology has obtained an implied license for a clinical trial and plans to develop a treatment for ankylosing spondylitis.


    The Center for Drug Evaluation (CDE) of the State Food and Drug Administration of China has announced that the IMG-020 injection declared by Chuangxiang Biotechnology has obtained an implied license for a clinical trial and plans to develop a treatment for ankylosing spondylitis.


    In May 2020, Chuangxiang Bio announced that it has reached a global cooperation agreement with Affibody, and has obtained the exclusive development and commercialization rights of IMG-020 in Greater China (Mainland China, Hong Kong, Macau, Taiwan), South Korea and other countries and regions.


    According to a press release issued by Chuangxiang Bio, currently, IMG-020 has successfully completed a phase 2 clinical trial for psoriasis in Germany.


    This time, the clinical research indication approved by IMG-020 in China is ankylosing spondylitis.





    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.